JCR Pharmaceuticals Co., Ltd.
4552.T · JPX
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | ¥33,072,000 | ¥42,871,000 | ¥34,343,000 | ¥51,082,000 |
| % Growth | -22.9% | 24.8% | -32.8% | – |
| Cost of Goods Sold | ¥11,524,000 | ¥11,620,000 | ¥8,886,000 | ¥10,461,000 |
| Gross Profit | ¥21,548,000 | ¥31,251,000 | ¥25,457,000 | ¥40,621,000 |
| % Margin | 65.2% | 72.9% | 74.1% | 79.5% |
| R&D Expenses | ¥15,431,000 | ¥11,234,000 | ¥8,802,000 | ¥7,175,000 |
| G&A Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| SG&A Expenses | ¥12,958,000 | ¥12,486,000 | ¥11,678,000 | ¥13,511,000 |
| Sales & Mktg Exp. | ¥0 | ¥0 | ¥0 | ¥0 |
| Other Operating Expenses | ¥0 | ¥0 | ¥0 | ¥0 |
| Operating Expenses | ¥28,389,000 | ¥23,720,000 | ¥20,480,000 | ¥20,686,000 |
| Operating Income | -¥6,841,000 | ¥7,532,000 | ¥4,975,000 | ¥19,933,000 |
| % Margin | -20.7% | 17.6% | 14.5% | 39% |
| Other Income/Exp. Net | ¥236,000 | -¥288,000 | ¥437,000 | -¥529,000 |
| Pre-Tax Income | -¥6,414,000 | ¥7,244,000 | ¥5,412,000 | ¥19,404,000 |
| Tax Expense | -¥1,718,000 | ¥1,707,000 | ¥1,625,000 | ¥4,886,000 |
| Net Income | -¥4,758,000 | ¥5,507,000 | ¥3,772,000 | ¥14,507,000 |
| % Margin | -14.4% | 12.8% | 11% | 28.4% |
| EPS | -38.43 | 44.13 | 30.34 | 117.26 |
| % Growth | -187.1% | 45.5% | -74.1% | – |
| EPS Diluted | -38.43 | 43.92 | 30.22 | 116.79 |
| Weighted Avg Shares Out | 123,826 | 124,790 | 124,308 | 123,720 |
| Weighted Avg Shares Out Dil | 123,826 | 125,397 | 124,838 | 124,209 |
| Supplemental Information | – | – | – | – |
| Interest Income | ¥113,000 | ¥111,000 | ¥33,000 | ¥7,000 |
| Interest Expense | ¥155,000 | ¥86,000 | ¥44,000 | ¥45,000 |
| Depreciation & Amortization | ¥3,374,000 | ¥3,197,000 | ¥1,997,000 | ¥1,945,000 |
| EBITDA | -¥2,885,000 | ¥10,528,000 | ¥7,453,000 | ¥21,394,000 |
| % Margin | -8.7% | 24.6% | 21.7% | 41.9% |